维奈克拉联合去甲基化药物治疗髓系肉瘤5例临床疗效及安全性分析
Efficacy and safety of venetoclax and hypomethylating agents in myeloid sarcoma
宋宝全 1宗李红 1孔金玉 1孔欣 1张剑 1陈君 2仇惠英1
作者信息
- 1. 苏州大学附属第一医院血液内科,江苏省血液研究所,国家血液系统疾病临床医学研究中心(江苏苏州,215000)
- 2. 苏州市永鼎医院
- 折叠
摘要
目的:探讨维奈克拉联合去甲基化药物治疗髓系肉瘤的有效性及安全性.方法:纳入5例髓系肉瘤患者,其中初诊患者2例,复发难治患者2例,造血干细胞移植后1例.3例给予维奈克拉联合地西他滨,2例给予维奈克拉联合阿扎胞苷,分析临床疗效及安全性.结果:5例患者治疗后病灶超声影像学消失,4例伴有骨髓侵犯均获得完全缓解,不良反应主要为骨髓抑制.截至随访终止日期,4例患者存活,1例患者后因本病复发死亡.结论:维奈克拉联合去甲基化药物治疗髓系肉瘤可取得较好的临床疗效,且无明显不良反应.
Abstract
Objective:To evaluate the efficacy and safety of venetoclax and hypomethylating agents in the treatment of myeloid sarcoma.Methods:The clinical data of 5 patients with myeloid sarcoma treated with veneto-clax and hypomethylating agents were retrospectively analyzed,among them one patient was isolated myeloid sar-coma after allogeneic hematopoietic cell transplantation,the others were accompanied by bone marrow involve-ment.Results:All the patients got lesions disappeared,4 cases with bone marrow invasion achieved complete re-mission,and the main adverse events were bone marrow suppression.By the end of follow-up,four patients were alive and one patient died of subsequent recurrence.Conclusion:The combination of venetoclax and hypomethylat-ing agents can achieve good clinical efficacy in the treatment of myeloid sarcoma,without significant adverse e-vents.
关键词
髓系肉瘤/维奈克拉/去甲基化药物/造血干细胞移植Key words
myeloid sarcoma/venetoclax/hypomethylating agents/hematopoietic stem cell transplantation引用本文复制引用
基金项目
江苏省老年健康科研项目(LKM2023015)
苏州市科技发展计划(医学创新应用研究)(SKY2022134)
出版年
2024
NETL
NSTL
万方数据